Target intelligence / Profile preview

Delta-like protein 3 (DLL3)

Target: DLL3
Molecular classification: Transmembrane protein, Notch ligand family

Overview

Delta-like protein 3 (DLL3) is an inhibitory Notch ligand involved in embryonic development and vertebral segmentation. It is highly expressed in certain neuroendocrine tumors, making it a therapeutic target. DLL3 binds to NOTCH receptors primarily within the same cell and inhibits NOTCH pathway activation. High levels of DLL3 are associated with SCLC morphology and correlate with neuroendocrine marker expression.

Mechanism of action

DLL3 binds to NOTCH receptors within the same cell, inhibiting NOTCH pathway activation. Antibody-drug conjugates targeting DLL3 deliver cytotoxic payloads upon internalization.

Biological functions

Inhibition of Notch signalingRegulation of somitogenesisEmbryonic development

Disease associations

Jarcho-Levin syndromeSmall cell lung cancer (SCLC)Pulmonary carcinoid tumorsMerkel cell carcinoma (MCC)Neuroendocrine prostate cancer

Safety considerations

Potential for off-target effects due to Notch pathway involvement in various tissuesToxicities associated with antibody-drug conjugates

Interacting drugs

Rovalpituzumab tesirine

1 more in the full profile.

Biomarkers

DLL3 expression level in tumors

Beyond the preview

Go deeper on Delta-like protein 3 (DLL3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Delta-like protein 3 (DLL3).

Explore the full profile